The KLHL26 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product delivers a loss-of-function model for KLHL26 via CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of cells bearing targeted mutations across the KLHL26 locus. The polyclonal format captures diverse knockout alleles, enabling population-level analyses of KLHL26 function without clonal bias.
The parental A-549 cell line originates from a 58-year-old Caucasian male with lung adenocarcinoma and harbors a KRAS G12S mutation while retaining wild-type EGFR. A-549 cells serve as an established model of human type II alveolar epithelial cells and are broadly utilized in respiratory disease and oncology research, particularly for investigating signaling pathways driving lung tumorigenesis and therapeutic responses.
KLHL26 functions as a substrate-specific adaptor for the Cullin3-RING E3 ubiquitin ligase (CRL3) complex. By binding CUL3 and RBX1, it recruits target proteins for K48-linked polyubiquitination, marking them for proteasomal degradation by the 26S proteasome. This activity is coordinated with E1 ubiquitin-activating enzymes (UBE1), E2 ubiquitin-conjugating enzymes (UBE2 family), and deubiquitinating enzymes such as USP14. Through this process, KLHL26 modulates the stability of regulators governing cell cycle progression and apoptosis, with its own expression likely controlled by stress-responsive transcription factors.
In the context of A-549 lung adenocarcinoma cells, disrupting KLHL26 provides insights into how ubiquitin-proteasome system dysfunction influences cancer cell behavior. Since KLHL26 is implicated in controlling proliferation and survival pathways, the knockout model helps elucidate its potential role in lung adenocarcinoma pathology, especially in the presence of oncogenic KRAS signaling. This model therefore aids in dissecting the cross-talk between oncogenic drivers and protein homeostasis networks.
Researchers can apply these polyclonal knockout cells to characterize KLHL26-dependent ubiquitination dynamics using co-immunoprecipitation and western blotting, identify novel substrates through quantitative proteomics, and assess impacts on cell cycle and apoptosis via flow cytometry. Functional assays such as colony formation and proteasome activity measurements further enable drug target validation for ubiquitin/proteasome pathway inhibitors. Transcriptomic approaches like RNA-seq complement these analyses. For further inquiries or technical support, please contact Ascent Research.
